Teva's UZEDY Linked To Fewer Emergency Visits And Lower Healthcare Costs In Real-World Study

Teva reported real-world data indicating that its UZEDY schizophrenia treatment helped patients remain on therapy longer while reducing emergency-room visits, hospitalizations and total healthcare costs versus certain alternative treatments. The findings support UZEDY's clinical and pharmacoeconomic value proposition, though the article did not provide specific outcome or cost-reduction figures.